Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Rutie Yin, Dr.
CONTACT
Lead
West China Second University Hospital
The efficacy of chemotherapy combined with anti-angiogenic agents in the treatment of platinum-resistant recurrent ovarian cancer has been demonstrated in clinical studies, and QL1706 acts as a bi-functional combination antibody that blocks both PD-1 and CTLA-4, in other cancer trials that have been conducted, it is expected that better efficacy and adverse event rates comparable to those of anti-PD-1 mabs and anti-CTLA-4 mabs will be achieved with combination chemotherapy and anti-angiogenic drugs, it may be possible to obtain better anti-tumor effects in platinum-resistant recurrent ovarian cancer patients.
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted